AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32066345 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided radiotherapy (MRgRT)
Number of subjects: 9
Study 32066345 — intervention group
Group type: COMPARATOR
Intervention: Linear accelerator (standard treatment)
Number of subjects: 9
Study 34453327 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV-PG/AQ
Number of subjects: 44
Study 34453327 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV-PG
Number of subjects: 44
Study 34453327 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ
Number of subjects: 44
Study 34453327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 33279295 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet group (treatment)
Number of subjects: 0
Study 33279295 — intervention group
Group type: COMPARATOR
Intervention: Non-quiet group (control)
Number of subjects: 0
Study 33279295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 0
Study 35294126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE50)
Number of subjects: 404
Study 35294126 — intervention group
Group type: COMPARATOR
Intervention: Control group (Naoxinqing tablet - NXQ)
Number of subjects: 404
Study 32941704 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram for predicting overall survival (OS) rates
Number of subjects: 66192
Study 32941704 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram for predicting 3- and 5-year OS rates
Number of subjects: 66192
Study 32941704 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram for predicting OS
Number of subjects: 66192
Study 32941704 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram
Number of subjects: 66192
Study 35669313 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate Intramuscular Injection (DMPA-IM)
Number of subjects: 401
Study 35669313 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Implant (LNG)
Number of subjects: 401
Study 35669313 — intervention group
Group type: COMPARATOR
Intervention: Copper Intrauterine Device (IUD)
Number of subjects: 401
Study 32701954 — intervention group
Group type: EXPERIMENTAL
Intervention: GoActive intervention (12-week school-based programme)
Number of subjects: 2862
Study 32701954 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard school practice)
Number of subjects: 2862
Study 32701954 — intervention group
Group type: EXPERIMENTAL
Intervention: GoActive intervention
Number of subjects: 2862
Study 35634761 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied over M1 cortex (2 mA, 20 min for 3 days)
Number of subjects: 67
Study 35634761 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied over left DLPFC (2 mA, 20 min for 3 days)
Number of subjects: 67
Study 35634761 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 67
Study 33723346 — intervention group
Group type: EXPERIMENTAL
Intervention: 1E10 CFU of E. coli strain E1392/75-2A
Number of subjects: 0
Study 33723346 — intervention group
Group type: EXPERIMENTAL
Intervention: 5E10 CFU of E. coli strain E1392/75-2A
Number of subjects: 0
Study 33723346 — intervention group
Group type: EXPERIMENTAL
Intervention: 1E10 CFU of E. coli (second challenge)
Number of subjects: 0
Study 32719903 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY-ND (fingolimod-nondaily)
Number of subjects: 72
Study 32719903 — intervention group
Group type: COMPARATOR
Intervention: FTY-ED (fingolimod-everyday)
Number of subjects: 72
Study 35043663 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rhythm control (n=194)
Number of subjects: 300
Study 33852718 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod
Number of subjects: 50
Study 33852718 — intervention group
Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 50
Study 33804409 — intervention group
Group type: EXPERIMENTAL
Intervention: High social status condition
Number of subjects: 132
Study 33804409 — intervention group
Group type: COMPARATOR
Intervention: Low social status condition
Number of subjects: 132
Study 36399962 — intervention group
Group type: EXPERIMENTAL
Intervention: Depictions of male, older, and heroin deaths
Number of subjects: 1280
Study 36399962 — intervention group
Group type: EXPERIMENTAL
Intervention: Older decedent (ecstasy)
Number of subjects: 1280
Study 36399962 — intervention group
Group type: EXPERIMENTAL
Intervention: Older ecstasy decedent
Number of subjects: 1280
Study 32930994 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1113
Study 32930994 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1113
Study 32930994 — intervention group
Group type: COMPARATOR
Intervention: Open-label treatment (previous placebo)
Number of subjects: 1113
Study 32930994 — intervention group
Group type: COMPARATOR
Intervention: Open-label treatment (previous 120 mg)
Number of subjects: 1113
Study 32930994 — intervention group
Group type: COMPARATOR
Intervention: Open-label treatment (previous 240 mg)
Number of subjects: 1113
Study 33115727 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic suture gastroplasty (E‐ESG)
Number of subjects: 71
Study 33115727 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification alone (control group)
Number of subjects: 71
Study 35175308 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Methylprednisolone (IVMP)
Number of subjects: 419
Study 35175308 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 419
Study 32888343 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic tablets
Number of subjects: 41866
Study 32888343 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil
Number of subjects: 41866
Study 32552839 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed checklist for brain-dead potential organ donor management
Number of subjects: 63
Study 32552839 — intervention group
Group type: COMPARATOR
Intervention: Standard ICU care
Number of subjects: 63
Study 35554079 — intervention group
Group type: EXPERIMENTAL
Intervention: TrimRox, a stimulant‐ and sugar‐free Prodosomed® TRCAP21 nutraceutical technology, utilizing six standardized extracts.
Number of subjects: 9
Study 35554079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract).
Number of subjects: 9
Study 34513067 — intervention group
Group type: EXPERIMENTAL
Intervention: Inherited metabolic disease (IMD) diagnosed patients (Group 1, n=8)
Number of subjects: 20
Study 34513067 — intervention group
Group type: COMPARATOR
Intervention: Transient hyperammonemia patients (Group 2, n=12)
Number of subjects: 20
Study 34513067 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic model for predicting IMD risk
Number of subjects: 20
Study 34513067 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia in infants with IMD
Number of subjects: 20
Study 34872339 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 310
Study 33370864 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults from urban areas
Number of subjects: 3977
Study 33370864 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 3977
Study 33370864 — intervention group
Group type: EXPERIMENTAL
Intervention: Married individuals
Number of subjects: 3977
Study 33370864 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with tertiary education
Number of subjects: 3977
Study 33370864 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployed individuals
Number of subjects: 3977
Study 33370864 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosed with hypertension
Number of subjects: 3977
Study 33370864 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosed with diabetes mellitus
Number of subjects: 3977
Study 33759620 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h TRF (eating only between 3 and 7 p.m.)
Number of subjects: 49
Study 33759620 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h TRF (eating only between 1 and 7 p.m.)
Number of subjects: 49
Study 33759620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no meal timing restrictions)
Number of subjects: 49
Study 33759620 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h TRF
Number of subjects: 49
Study 33759620 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h TRF
Number of subjects: 49
Study 33480964 — intervention group
Group type: EXPERIMENTAL
Intervention: Restarting antiplatelet treatment in patients with intracerebral haemorrhage
Number of subjects: 0
Study 33480964 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 0
Study 33480964 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion
Number of subjects: 0
Study 34585215 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose 10 mg/kg intravenous
Number of subjects: 61
Study 34585215 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose 20 mg/kg intravenous
Number of subjects: 61
Study 34585215 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose 40 mg/kg intravenous
Number of subjects: 61
Study 34585215 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses 10 mg/kg every 2 weeks for 24 weeks
Number of subjects: 61
Study 34585215 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses 10 mg/kg every 4 weeks for 72 weeks
Number of subjects: 61
Study 34585215 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses 20 mg/kg every 4 weeks for 72 weeks
Number of subjects: 61
Study 34585215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 33067698 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib, melphalan, and prednisone (D-VMP)
Number of subjects: 350
Study 33067698 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC) regimens (bortezomib- or thalidomide-based)
Number of subjects: 350
Study 34347564 — intervention group
Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO intervention
Number of subjects: 311
Study 34347564 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 311
Study 32416073 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg every 2 weeks)
Number of subjects: 457
Study 32416073 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (docetaxel 75 mg/m2 every 3 weeks or irinotecan 180 mg/m2 every 2 weeks)
Number of subjects: 457
Study 35682322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 388
Study 34135015 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide plus metformin (L+M)
Number of subjects: 358
Study 34135015 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric band surgery (LB)
Number of subjects: 358
Study 34135015 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 358
Study 34135015 — intervention group
Group type: COMPARATOR
Intervention: Glargine followed by metformin (G/M)
Number of subjects: 358
Study 34135015 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 358
Study 34379025 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral herbal supplement 1650 mg/day
Number of subjects: 55
Study 34379025 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral herbal supplement 3300 mg/day
Number of subjects: 55
Study 34379025 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3300 mg/day
Number of subjects: 55
Study 34952747 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored contingency management (CM) intervention targeting alcohol abstinence; 12 weeks duration, incentives for negative urine tests (EtG < 150 ng/mL)
Number of subjects: 158
Study 34952747 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent (NC) Control group; 12 weeks duration, incentives for submitting urine samples regardless of abstinence
Number of subjects: 158
Study 34952747 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored contingency management (CM) intervention targeting alcohol abstinence
Number of subjects: 158
Study 33043352 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous concentrated growth factor fibrin solution + Bio‐Oss bone powder
Number of subjects: 83
Study 33043352 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Oss bone powder alone
Number of subjects: 83
Study 34979216 — intervention group
Group type: COMPARATOR
Intervention: Protons
Number of subjects: 186
Study 34979216 — intervention group
Group type: COMPARATOR
Intervention: Photons
Number of subjects: 186
Study 32174349 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe adapter
Number of subjects: 20
Study 32174349 — intervention group
Group type: COMPARATOR
Intervention: Ring‐finger method
Number of subjects: 20
Study 32174349 — intervention group
Group type: COMPARATOR
Intervention: Middle‐finger method
Number of subjects: 20
Study 34390049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program
Number of subjects: 120
Study 34390049 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study 35098554 — intervention group
Group type: EXPERIMENTAL
Intervention: NP001
Number of subjects: 138
Study 35098554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 36468339 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week online psychosocial intervention
Number of subjects: 0
Study 36468339 — intervention group
Group type: COMPARATOR
Intervention: Contact control group
Number of subjects: 0
Study 34217230 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention to reduce inappropriate psychotropic drug use
Number of subjects: 0
Study 34217230 — intervention group
Group type: EXPERIMENTAL
Intervention: External coaching
Number of subjects: 0
Study 34217230 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation performance
Number of subjects: 0
Study 34217230 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 0
Study 32762997 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to Think (TTT)
Number of subjects: 613
Study 32762997 — intervention group
Group type: COMPARATOR
Intervention: No Time to Think (NTTT)
Number of subjects: 613
Study 35863993 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia-based education (MBE) including watching two videos followed by focused physician counseling
Number of subjects: 75
Study 35863993 — intervention group
Group type: COMPARATOR
Intervention: Standard physician education (SPE)
Number of subjects: 75
Study 33388204 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich diet (PR-diet)
Number of subjects: 66
Study 33388204 — intervention group
Group type: COMPARATOR
Intervention: Control diet (C-diet)
Number of subjects: 66
Study 34445969 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (DA) on treatment of depression
Number of subjects: 504
Study 34445969 — intervention group
Group type: COMPARATOR
Intervention: No decision aid (Control)
Number of subjects: 504
Study 34445969 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched treatment preference
Number of subjects: 504
Study 34445969 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding taking anti-depressants
Number of subjects: 504
Study 35396313 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual exercise prehabilitation intervention
Number of subjects: 0
Study 34872085 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood kidney injury molecule 1 (KIM-1)
Number of subjects: 5131
Study 34872085 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening kidney function (WKF)
Number of subjects: 5131
Study 35983809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg every 3 days
Number of subjects: 58
Study 35983809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 32735704 — intervention group
Group type: EXPERIMENTAL
Intervention: HL151 (20 mg orally once daily for 4 weeks)
Number of subjects: 272
Study 32735704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 33211519 — intervention group
Group type: EXPERIMENTAL
Intervention: RTM (Reconsolidation of Traumatic Memories)
Number of subjects: 30
Study 33211519 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study 35700205 — intervention group
Group type: EXPERIMENTAL
Intervention: Olotillo × Tuxpeño race in Myroxylon with 2.8 m × 2.0 arrays and monoculture
Number of subjects: 0
Study 35700205 — intervention group
Group type: COMPARATOR
Intervention: Three native maize races
Number of subjects: 0
Study 35700205 — intervention group
Group type: EXPERIMENTAL
Intervention: Agroforestry systems (ASs)
Number of subjects: 0
Study 34302350 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal cholecalciferol (vitamin D-3) dose of 0, 4200, 16,800, or 28,000 IU/wk from 17 to 24 wk of gestation followed by placebo to 6 mo postpartum
Number of subjects: 1300
Study 34302350 — intervention group
Group type: EXPERIMENTAL
Intervention: 28,000 IU cholecalciferol/wk both prenatally and postpartum
Number of subjects: 1300
Study 34302350 — intervention group
Group type: COMPARATOR
Intervention: Various biological, sociodemographic, and laboratory-related characteristics including feeding practices
Number of subjects: 1300
Study 32657608 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective Response (OR)
Number of subjects: 596
Study 32657608 — intervention group
Group type: COMPARATOR
Intervention: Non-Objective Response (non-OR)
Number of subjects: 596
Study 36107466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sucroferric oxyhydroxide (2000 mg/day)
Number of subjects: 28
Study 36107466 — intervention group
Group type: COMPARATOR
Intervention: Washout (control)
Number of subjects: 28
Study 33648870 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal-specific oral nutritional supplement (RS-ONS) during hemodialysis sessions, given in two portions: 100 mL after 1 hour and 137 mL 45 minutes before the end of hemodialysis.
Number of subjects: 36
Study 33648870 — intervention group
Group type: COMPARATOR
Intervention: Renal-specific oral nutritional supplement (RS-ONS) at home.
Number of subjects: 36
Study 32960094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 86% v/v gel
Number of subjects: 18
Study 32960094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 89.5% v/v solution
Number of subjects: 18
Study 32960094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 72.4% v/v solution
Number of subjects: 18
Study 32960094 — intervention group
Group type: COMPARATOR
Intervention: Reference solution (70% v/v ethanol)
Number of subjects: 18
Study 35713119 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ESWT
Number of subjects: 99
Study 35713119 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial ESWT
Number of subjects: 99
Study 35713119 — intervention group
Group type: COMPARATOR
Intervention: Sham ESWT
Number of subjects: 99
Study 33380179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 105
Study 33380179 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented fixation
Number of subjects: 105
Study 33380179 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid fixation
Number of subjects: 105
Study 33380179 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 105
Study 32912948 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced, personalised smoking cessation support package including CT scan images
Number of subjects: 1040
Study 32912948 — intervention group
Group type: COMPARATOR
Intervention: Standard best practice smoking cessation support
Number of subjects: 1040
Study 35123362 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) delivered via telehealth for 4 weeks
Number of subjects: 27
Study 35123362 — intervention group
Group type: COMPARATOR
Intervention: Monitoring control
Number of subjects: 27
Study 34347132 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g per day for 40 days)
Number of subjects: 329
Study 34347132 — intervention group
Group type: COMPARATOR
Intervention: Control group (without vitamin C)
Number of subjects: 329
Study 35799672 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sorafenib combined with transcatheter arterial chemoembolization (TACE)
Number of subjects: 88
Study 35799672 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE) only
Number of subjects: 88
Study 35799672 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI
Number of subjects: 88
Study 35799672 — intervention group
Group type: COMPARATOR
Intervention: MR plain scan
Number of subjects: 88
Study 32428656 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine use
Number of subjects: 634
Study 32428656 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-medication with herbal medicines
Number of subjects: 634
Study 32428656 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal plant species reported
Number of subjects: 634
Study 32428656 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with herbal medicine use
Number of subjects: 634
Study 35856224 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg, once a day, orally)
Number of subjects: 112
Study 33626105 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA score 1
Number of subjects: 11621
Study 33626105 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA score 2
Number of subjects: 11621
Study 33626105 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA score 3
Number of subjects: 11621
Study 33626105 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 11621
Study 33024552 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (three cups/day after meals) + usual treatment (deferasirox iron chelator and on demand blood transfusion)
Number of subjects: 68
Study 33024552 — intervention group
Group type: COMPARATOR
Intervention: Control (only usual treatment)
Number of subjects: 68
Study 33686922 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress‐intervention condition
Number of subjects: 177
Study 33686922 — intervention group
Group type: COMPARATOR
Intervention: Stress‐placebo condition
Number of subjects: 177
Study 33686922 — intervention group
Group type: COMPARATOR
Intervention: No‐stress‐placebo control condition
Number of subjects: 177
Study 35201674 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 668